“`html
Efficacy and Safety of Choline Alfoscerate in Preventing Dementia in Elderly Patients
Key Findings:
Over a three-year period, a study involving 100 patients with mild cognitive impairment (aMCI) showed that annual therapy with choline alfoscerate (CA) had a significant preventive effect on the progression to clinically pronounced dementia. Patients receiving CA therapy experienced a lower progression of cognitive deficits (12.2% compared to 39.1% in the non-therapy group) and a lower conversion rate to dementia (8.2% compared to 26.1%). The cognitive functioning indicators in the CA therapy group showed significant improvement throughout the follow-up period in comparison to the non-therapy group.
Conclusion:
The study results suggest that CA therapy may serve as a model for preventive dementia treatment, particularly for individuals at high risk of developing Alzheimer’s disease.
Value: This research provides insights into a potential therapy for preventing the progression of cognitive deficits and the development of dementia in individuals with aMCI, offering practical solutions for managing and expanding services for elderly patients.
“`
